In News

Follow this topic

Bookmark

Record learning outcomes

The Scottish Medicines Consortium (SMC) has accepted Harvoni (ledipasvir 90mg/ sofosbuvir 400mg) for the treatment of adult patients with chronic hepatitis C genotype 1 and 4 infection, after concluding that it represents good value for money for NHS Scotland. Licensed in November 2014, Harvoni is the first and only once daily, single tablet regimen to treat the majority of hepatitis C genotype 1 and 4 patients. It has been shown in clinical trials to cure up to 99 per cent of patients with compensated genotype 1 infection in eight, 12 or 24 weeks (dependent on prior treatment history and cirrhosis status), says maker Gilead Sciences.